In the news - Cerevel Therapeutics
Jul 27, 2020 · Cerevel will utilize Cyclica’s Ligand Express ® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines
In the news - Cerevel Therapeutics
Aug 14, 2019 · Cerevel Therapeutics has a diversified pipeline comprising three clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including epilepsy, Parkinson’s, Alzheimer’s, schizophrenia and addiction.
News & Announcements | Cerevel Therapeutics
Apr 18, 2024 · Cerevel is now part of AbbVie. Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders. Read the press release
Cerevel Therapeutics Expands Its Board of Directors - Cerevel …
Dec 20, 2018 · “Cerevel seeks to expand treatment options in a therapeutic area where there is an urgent unmet need for patients, and we are delighted to have the support and guidance of these exceptional leaders as we move forward,” said Adam Koppel, Managing Director of Bain Capital and member of the Board.
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial …
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open.
Cerevel Therapeutics to Present Results from a Phase 2 Study of ...
Sep 19, 2019 · Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and addiction.
In the news - Cerevel Therapeutics
Jan 30, 2020 · Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s disease, …
In the news - Cerevel Therapeutics
Dr. Sanchez joins Cerevel Therapeutics from Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC), where he most recently served as senior vice president, global clinical development and was also appointed as chief medical officer of Avanir Pharmaceuticals during the last half of his 11-year tenure at Otsuka.
In the news - Cerevel Therapeutics
Nov 4, 2019 · Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and …
Job Description - Cerevel Therapeutics
Open positions Cerevel is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, non-disqualifying physical or mental disability, national origin, veteran status or any other characteristic protected by …